Reviewing Arsanis Inc. (ASNS)’s and Mustang Bio Inc. (NASDAQ:MBIO)’s results

Both Arsanis Inc. (NASDAQ:ASNS) and Mustang Bio Inc. (NASDAQ:MBIO) are Biotechnology companies, competing one another. We will contrast their institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Arsanis Inc. N/A 0.00 44.86M -3.14 0.00
Mustang Bio Inc. N/A 2411.40 34.49M -1.30 0.00

Demonstrates Arsanis Inc. and Mustang Bio Inc. earnings per share, gross revenue and valuation.


Table 2 provides the net margins, return on equity and return on assets of the two firms.

Net Margins Return on Equity Return on Assets
Arsanis Inc. 0.00% -103.8% -70.8%
Mustang Bio Inc. 0.00% -65.1% -60%


5.1 and 5.1 are the respective Current Ratio and a Quick Ratio of Arsanis Inc. Its rival Mustang Bio Inc.’s Current and Quick Ratios are 10.3 and 10.3 respectively. Mustang Bio Inc. has a better chance of clearing its pay short and long-term debts than Arsanis Inc.

Institutional and Insider Ownership

The shares of both Arsanis Inc. and Mustang Bio Inc. are owned by institutional investors at 75.5% and 10.3% respectively. Arsanis Inc.’s share owned by insiders are 1.8%. On the other hand, insiders owned about 0.7% of Mustang Bio Inc.’s shares.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Arsanis Inc. -7.46% 160.87% 101.12% -80.12% -73.33% -71.79%
Mustang Bio Inc. -17.46% -32.03% -48.76% -52.85% -69.88% -72.39%

For the past year Arsanis Inc.’s stock price has smaller decline than Mustang Bio Inc.


On 6 of the 7 factors Mustang Bio Inc. beats Arsanis Inc.

Arsanis, Inc., a clinical-stage biopharmaceutical company, focuses on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. Its lead product candidate is ASN100, a first-in-class mAb therapeutic in Phase II clinical development for the prevention of staphylococcus aureus pneumonia. The company's preclinical pipeline comprises mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus. Arsanis, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.